Lightning Round: Clorox, Donaldson, Hanesbrands and More

Clorox : Cramer called the quarter “disappointing” but said he can’t recommend selling the stock at this low level, especially with the 3.5-percent dividend yield.

Meridian Biosciences : Cramer is bullish on diagnostic companies like VIVO and Becton Dickinson.

Lightning Round
Lightning Round

Donaldson : “Donaldson’s terrific,” Cramer said.

Genpact : Cramer said there is no catalyst coming for Genpact that makes the stock worth recommending.

Micron Technology : Sell MU. “I would much rather have you in any Internet tsunami name that I’ve been recommending,” Cramer said.

Qwest Communications : Cramer likes Qwest’s 4.5-percent dividend yield, as well as the fact that if it merges with CenturyTel investors will get shares of that company. He’s bullish on CTL, which yields 6.7 percent.

Celgene : Cramer thinks the dip in Celgene’s share price, caused by negative news about the company’s Revlimid blood-cancer treatment, is an opportunity to buy the stock. “I think this stock is going to come back,” he said.

Hanesbrands : Go with Warnaco instead, Cramer said.

Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com

Cramer's New Book